



# LUNG CANCER RESEARCH PROGRAM

FY24  
Appropriation  
**\$25M**

**MISSION:** Support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, management, and treatment for the control and cure of lung cancer




## FY24 Funding Mechanisms

|   |  |  |  |  |
|---|--|--|--|--|
|  <p><b>Concept Award</b><br/><b>\$120K</b></p> |  <p><b>Career Development Award</b><br/><b>\$375K</b></p> |  <p><b>Idea Development Award with New and Established Investigators</b><br/><b>\$525K</b><br/><i>supports innovative, high-impact ideas in early development</i></p> |  <p><b>Translational Research Award</b><br/><b>\$900K</b><br/>TRA with clinical trial<br/><b>\$1.2M</b></p> |  <p><b>Patient-Centered Outcomes and Survivorship Award</b><br/><b>\$650K</b></p> |
|---|--|--|--|--|

## FY24 Deadlines

| CONCEPT AND CDA | <b>28 May 2024</b><br>Letter of Intent Due  | <b>17 June 2024</b><br>Full Applications Due  | <b>July 2024</b><br>Peer Review      | <b>October 2024</b><br>Programmatic Review  |
|-----------------|---|---|--------------------------------------|---|
| IDA AND TRA     | <b>28 May 2024</b><br>Pre-Application Due   | <b>7 August 2024</b><br>Full Applications Due | <b>September 2024</b><br>Peer Review | <b>December 2024</b><br>Programmatic Review |
| PCOSA           | <b>17 July 2024</b><br>Letter of Intent Due | <b>7 August 2024</b><br>Full Applications Due | <b>September 2024</b><br>Peer Review | <b>December 2024</b><br>Programmatic Review |

## Areas of Emphasis

| Biology and Etiology  | Prevention  | Detection, Diagnosis and Surveillance  | Treatment and Prognosis  | Health Outcomes and Survivorship  | Disparities   |
|---|---|--|--|---|---|
| <p>Understand the molecular mechanisms of initiation and progression to lung cancer</p> <p>Understand contributors to lung cancer development other than tobacco</p> <p>Understand the biology of metastatic/ oligometastatic disease progression</p> | <p>Identify innovative strategies for prevention of occurrence, recurrence of, or metastases from lung cancer</p>  | <p>Improve approaches to screening and early detection of lung cancer</p> <p>Identify strategies for prompt detection and/or characterization of progressive disease</p>  | <p>Identify innovative strategies for treatment, including overcoming resistance</p> <p>Develop or optimize biomarkers to assist with therapeutic decision-making</p> <p>Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer</p> | <p>Identify and understand long-term and cumulative effects of lung cancer and its treatment(s) on patients, families, and support systems with respect to the impact on QoL</p> <p>Identify and understand impact of comorbidities on survivorship care in all stages of lung cancer</p> | <p>Advance equity and reduce lung cancer disparities among underserved and underrepresented populations</p>  |

For more information, visit: <https://cdmrp.health.mil/funding/lcrp>

